EBOS GROUP LIMITED — Annual Report 2024

Aug 20, 2024

Results announcement

==> picture [101 x 49] intentionally omitted <==

==> picture [120 x 76] intentionally omitted <==

(for Equity Security issuer/Equity and Debt Security issuer)

Results for announcement to the market
Name of issuer	EBOS Group Limited
Reporting Period	12 months to 30 June 2024
Previous Reporting Period	12 months to 30 June 2023
Currency	AUD
	Amount (AUD $000s)	Percentage change
Revenue from continuing operations	$13,189,054	7.8%
Total Revenue	$13,189,054	7.8%
Underlying Net Profit after Tax from continuing operations attributable to security holders1	$303,405	7.7%
Net profit/(loss) from continuing operations	$271,549	7.2%
Total net profit/(loss)	$271,549	7.2%
Final Dividend
Amount per Quoted Equity Security	NZD $0.61500000
Imputed amount per Quoted Equity Security	NZD $0.05979167
Record Date	30 August 2024
Dividend Payment Date	18 September 2024
	Current period	Prior comparable period
Net tangible assets per Quoted Equity Security2	AUD($4.18)	AUD($3.53)
A brief explanation of any of the figures above necessary to enable the figures to be understood	Refer to the audited Consolidated Financial Report, Results Presentation and Results Media Release for EBOS Group Limited for the financial year ended 30 June 2024, issued on 21 August 2024.
Authority for this announcement
Name of person authorised to make this announcement	Janelle Cain
Contact person for this announcement	Janelle Cain
Contact phone number	+61 3 9918 5370
Contact email address	Janelle.Cain@ebosgroup.com
Date of release through MAP	21 August 2024

Consolidated Financial Statements accompany this announcement.

1 Underlying Net Profit after Tax represents reported profit for the period adjusted for one-off M&A costs ($10.1m pre tax, $7.5m post tax) primarily associated with a large strategic transaction which did not proceed, non-recurring restructuring costs and site transition costs (which primarily includes staff redundancies) to enable future underlying growth ($8.6m pre tax, $6.1m post tax) and the amortisation (non-cash) expense attributable to the LifeHealthcare acquisition purchase price accounting (PPA) of finite life intangible assets ($26.2m pre tax, $18.3m post tax). Refer to Appendix 1 for reconciliation between reported and underlying earnings.

2 Net Tangible Assets excludes A$389.0m (FY23: A$281.8m) of Right of Use assets, although includes A$407.2m (FY23: A$304.5m) of lease liabilities in relation to the adoption of NZ IFRS 16 ‘Leases’ .

Appendix 1:

Reconciliation of Reported to Underlying Earnings	30 June 2024	30 June 2023	Change
(Audited)	AUD$000	AUD$000	%
Reported EBITDA	605,595	568,776	6.5%
Add back underlying earnings adjustments in the period1	18,748	13,234
Underlying EBITDA	624,343	582,010	7.3%
Reported EBIT	476,724	443,992	7.4%
Add back underlying earnings adjustments in the period1	44,929	40,173
Underlying EBIT	521,653	484,165	7.7%
Reported PBT	383,103	373,431	2.6%
Add back underlying earnings adjustments in the period1	44,929	40,173
Underlying PBT	428,032	413,604	3.5%
Reported Net Profit after Tax (NPAT) attributable to owners of the Company	271,549	253,373	7.2%
Add back underlying earnings adjustments in the period1(net of tax and after non-controlling interests)	31,856	28,455
Underlying Net Profit after Tax (NPAT) attributable to owners of the Company	303,405	281,828	7.7%

1 Underlying EBITDA, Underling EBIT, Underling PBT and Underlying Net Profit after Tax attributable to the owners of the Company are non-GAAP measures. Underlying earnings for the 30 June 2024 period exclude one-off M&A costs ($10.1m pre tax, $7.5m post tax) primarily associated with a large strategic transaction which did not proceed, nonrecurring restructuring costs and site transition costs (which primarily includes staff redundancies) to enable future underlying growth ($8.6m pre tax, $6.1m post tax) and the amortisation (non-cash) expense attributable to the LifeHealthcare acquisition purchase price accounting (PPA) of finite life intangible assets ($26.2m pre tax, $18.3m post tax). Underlying earnings for the 30 June 2023 period exclude Medical Technology division integration costs ($12.5m pre tax, $8.9m post tax), one-off M&A costs ($0.7m pre tax, $0.7m post tax) and the amortisation (non-cash) expense attributable to the LifeHealthcare acquisition PPA of finite life intangible assets ($26.9m pre tax, $18.9m post tax).